Barclays PLC Has $934,000 Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Barclays PLC increased its stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 32.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 494,516 shares of the company’s stock after purchasing an additional 121,799 shares during the quarter. Barclays PLC owned approximately 0.40% of Mersana Therapeutics worth $934,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MRSN. State Street Corp grew its holdings in shares of Mersana Therapeutics by 1.6% during the third quarter. State Street Corp now owns 2,725,394 shares of the company’s stock worth $5,151,000 after purchasing an additional 43,339 shares during the last quarter. Renaissance Technologies LLC boosted its position in Mersana Therapeutics by 1.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,448,219 shares of the company’s stock worth $2,911,000 after buying an additional 20,400 shares during the period. Verition Fund Management LLC grew its holdings in Mersana Therapeutics by 11,695.2% during the 3rd quarter. Verition Fund Management LLC now owns 1,303,249 shares of the company’s stock worth $2,463,000 after acquiring an additional 1,292,200 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in Mersana Therapeutics by 104.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 993,046 shares of the company’s stock valued at $1,877,000 after acquiring an additional 507,453 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of Mersana Therapeutics by 16.0% during the third quarter. Wellington Management Group LLP now owns 618,305 shares of the company’s stock valued at $1,169,000 after acquiring an additional 85,439 shares during the last quarter. Institutional investors own 93.92% of the company’s stock.

Analyst Ratings Changes

MRSN has been the topic of several analyst reports. Wedbush reissued an “outperform” rating and issued a $4.00 price objective (down previously from $7.00) on shares of Mersana Therapeutics in a research note on Friday, January 10th. Citigroup assumed coverage on Mersana Therapeutics in a research note on Friday, November 15th. They issued a “buy” rating and a $5.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $5.57.

Mersana Therapeutics Stock Performance

Shares of Mersana Therapeutics stock opened at $0.63 on Wednesday. The business has a 50-day moving average price of $1.95 and a two-hundred day moving average price of $1.87. Mersana Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $6.28. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35. The company has a market cap of $78.32 million, a P/E ratio of -1.04 and a beta of 1.43.

Mersana Therapeutics (NASDAQ:MRSN) last released its earnings results on Wednesday, November 13th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The business had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $7.53 million. During the same quarter last year, the firm posted ($0.35) earnings per share. The firm’s revenue was up 63.6% on a year-over-year basis. As a group, analysts anticipate that Mersana Therapeutics, Inc. will post -0.61 EPS for the current year.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.